Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 7/20 | 0.47 |
| ▸ | ACP1 | P24666 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374541 | 0.91 | TNNI3K (0.47) | CYP1A2CYP3A4FGFR3CYP2C19JAK2 | |
| SCHEMBL374379 | 0.87 | KDM4E (0.46) | CYP1A2CYP3A4FGFR3CYP2C19JAK2 | |
| SCHEMBL2282067 | 0.85 | TNNI3K (0.66) | TNNI3K | |
| SCHEMBL15295501 | 0.81 | FGFR3 (0.59) | CYP1A2CYP3A4FGFR3CYP2C19JAK2 | |
| SCHEMBL5496809 | 0.80 | MC4R (0.59) | JAK2JAK3ACP1MC4RPTK2 | |
| Trifluoroacetic Acid SCHEMBL14323756 | 0.78 | TNNI3K (0.56) | CYP1A2CYP3A4FGFR3CYP2C19TNNI3K | |
| SCHEMBL374274 | 0.77 | TNNI3K (0.53) | CYP1A2CYP3A4FGFR3CYP2C19TNNI3K | |
| SCHEMBL4438331 | 0.77 | CCNT1 (0.55) | CYP1A2CYP3A4FGFR3CYP2C19JAK2 | |
| SCHEMBL4950163 | 0.77 | KDM1A (0.56) | JAK2JAK1JAK3 | |
| SCHEMBL374474 | 0.77 | METTL3 (0.47) | FGFR3JAK2JAK1TNNI3KJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | CYP1A2 1058/4885CYP3A4 2061/4885FGFR3 5/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | CYP1A2 1058/4885CYP3A4 2061/4885FGFR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.